Is there an upper age limit for bone marrow transplantation?

Bone Marrow Transplantation

Volumn 29, Issue 4, 2002, Pages 277-284

  Popplewell, L L ^a   Forman, S J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

GVHD; Mortality; Non myeloablative; Patient age; Survival; Transplant

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; ETOPOSIDE; FLUOROURACIL; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THIOTEPA; THYMOCYTE ANTIBODY; TOSITUMOMAB I 131;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW TRANSPLANTATION; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INDIVIDUALIZATION; LIVER VENOOCCLUSIVE DISEASE; MALE; MEDICAL DECISION MAKING; PRIORITY JOURNAL; PROGNOSIS; SHORT SURVEY; WHOLE BODY RADIATION;

ACUTE DISEASE; ADULT; AGE FACTORS; AGED; BONE MARROW TRANSPLANTATION; CHRONIC DISEASE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOCYTE DEPLETION; MIDDLE AGED; PROGNOSIS; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0036120766     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703382     Document Type: Short Survey

References (53)

1. Acute Leukemias
2. Myelodysplastic syndromes
3. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype
4. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1612 patients entered into the MRC AML 10 trial
5. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia
6. Revised classification of acute myeloid leukemia
7. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia (AML) on outcome of AML-type chemotherapy
8. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy
9. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia
10. Microsatellite instability and p53 mutations are associated with abnormal expression of the MSH2 gene in adult acute leukemia
11. The International non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma
12. Intensive postremission chemotherapy in adults with acute myeloid leukemia
13. Principal results of the medical research council's 8th acute myeloid leukemia trial
14. The association between high-dose cytarabine neurotoxicity and renal insufficiency
15. Risk factors for high-dose cytarabine neurotoxicity: An analysis of a cancer and leukemia group B trial in patients with acute myeloid leukemia
16. Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematologic malignancies
17. Randomized trial of filgrastim-mobilized peripheral blood progenitor cell transplantation versus autologous bone marrow transplantation in lymphoma patients
18. High-dose therapy and autologous bone marrow transplantation for intermediate and high grade non-Hodgkin's lymphoma in patients aged 55 years and over: Results from the European Group for Bone Marrow Transplantation
19. Autologous bone marrow transplantation for first remission acute myeloblastic leukemia in patients older than 50 years: A retrospective analysis of the European Bone Marrow Transplant Group
20. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide and autologous stem cell transplantation for relapsed B-cell lymphomas
21. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
22. Autotransplants in multiple myeloma: What have we learned?
23. Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities
24. The unique role of cytogenetics in the prognosis of patients with myeloma receiving high dose therapy and autotransplants
25. Age is not a prognostic variable with autotransplants for multiple myeloma
26. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years
27. Bone marrow transplantation for hematologic malignancies in patients aged 30 years or older
28. Bone marrow transplantation in patients aged 45 years and older
29. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time - A report of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
30. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age
31. Treatment of chronic myeloid leukemia by marrow transplantation
32. Marrow transplantation for chronic myeloid leukemia: The influence of plasma busulfan levels on the outcome of transplantation
33. Intravenous (IV) vs oral busulfan (Bu) as part of a BU/CY (cyclophosphamide) preparative regimen for allogeneic hematopoietic stem cell transplantation (HSCT): Decreased incidence of hepatic mortality and overall 100 day mortality
34. 131-I-anti-CD45 antibody plus busulfan/cyclophosphamide in matched related transplants for AML in first remission
35. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers
36. Risk factors for acute graft-versus-host disease
37. Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft-versus-host disease, relapse, and relapse-free survival
38. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation
39. Acute graft-versus-host disease: Analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate
40. Risk factors for acute graft-versus-host disease in 291 consecutive HLA-identical bone marrow transplant recipients
41. Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation
42. Predictive factors for chronic graft-versus-host disease after histocompatible sibling donor bone marrow transplantation
43. Risk factors for chronic graft-versus-hosts disease after bone marrow transplantation: A retrospective single centre analysis
44. Prognostic factors for long-term survival in leukemia marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease
45. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: Freedom from relapse in the absence of graft-versus-host disease
46. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: Effect of patient age and donor leukocyte infusions
47. Graft-versus-leukemia effect in man: The relapse rate of acute leukemia is lower after allogeneic than after syngeneic marrow transplantation
48. Retrospective evaluation of autologous bone marrow transplantation vs allogeneic bone marrow transplantation from an HLA identical related donor in acute myelocytic leukemia
49. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia
50. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia
51. Nonmyeloblative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases
52. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
53. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects